Oral factor Xa inhibitors are attractive options for preventing post-op thromboembolic disease, since they are given at a fixed dose and do not require serum monitoring. In this randomized trial, 3195 post-op total knee replacement patients were randomized to apixaban (2.5mg po BID) or enoxaparin (30mg SQ BID) for 10-14 days. The primary outcome (DVT, PE, or death) occurred in 9% in each group, with less bleeding in the apixaban group (3% vs 4%). Apixaban is a promising new oral agent for post-op thromboembolism prevention, pending FDA approval (abstract).
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]